Antiviral Clinical Trial for Long Covid-19

This study is testing if two existing antiviral medications, Truvada (tenofovir disoproxil/emtricitabine) and Selzentry, can help reduce symptoms in adults with Long Covid. Researchers believe that ongoing viral activity might play a role in Long Covid. You could be eligible if you are 18 or older, have a diagnosis of Long Covid, and had a confirmed or suspected COVID-19 infection at least six months ago. Participants will take either Truvada, Selzentry, or a placebo (an inactive pill) daily for 90 days. The main goal is to see if these medications improve your overall health and quality of life, as measured by a health questionnaire.

Study design: This study plans to enroll 90 participants. You will be randomly assigned to receive one of the two antiviral drugs or a placebo.
What's involved: You will take a study medication daily for 90 days. Your health will be assessed at screening, and again on days 60, 90, and 180.
Compensation: Not stated in the trial record.
Follow-up: Your health will be monitored for 180 days after the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Antiviral Clinical Trial for Long Covid-19

Recruiting

PHASE2Ages 18+Interventional

Icahn School of Medicine at Mount Sinai

~90 participants

Updated 2026-03-13 on ClinicalTrials.gov

What's tested:tenofovir disoproxil/emtricitabineSelzentryPlacebo

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale

Measured over at Screening, Day 60, Day 90, and Day 180

Conditions

Long Covid

NCT06511063

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)
New York, New Yorkstudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

David Putrino, PhD, PT · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

David Putrino, PhD, PT

[email protected]

212-241-8454

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Provision of signed and dated informed consent form

Stated willingness to comply with all study procedures and availability for the duration of the study

Any gender, aged 18+

Diagnosed with:

Long Covid

Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team

Formal diagnosis of Long Covid from a physician and a history of 6 months of Long COVID symptoms

At least a six-month history of one of the following symptoms following SARS-CoV-2 infection:

headache, memory loss, insomnia, mood disturbance, chest pain, palpitations, shortness of breath, cough, muscle pains, joint pains, or GI upset\] AND at least moderate fatigue (measured by Fatigue Severity Score) AND at least moderate post-exertional malaise (PEM) (measured by DePaul PEM screener)

Participants who are willing and able to comply with all data collection, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected before randomization as part of the baseline survey).

Exclusion

Pre-existing conditions including, but not limited to:

Autoimmune conditions such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.

A pre-2020 diagnosis of another Post-Acute Infectious Syndrome such as Chronic Lyme disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, etc.

Documented history of vaccine injury

Or any other chronic condition that has the potential to impact on immunological profiling, at the discretion of the research physician

HIV+ status

Current use of either Truvada or Selzentry

Taking a medication, within 6 weeks, with known interactions with Truvada or Selzentry including but not limited to: Acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple NSAIDs or chronic high dose NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir, or other drugs that significantly affect renal function

Current treatment with drugs known to affect EBV replication, including but not limited to: Acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, teriflunomide, interferon

Known allergic reactions to components of Truvada or Selzentry

Febrile illness within the last 3 months of planned baseline evaluation

Treatment with another investigational drug or other investigational intervention within 6 months of planned baseline evaluation

Immunosuppressed individuals (transplant on antiviral prophylaxis and/or patients taking immunosuppressive medications such as steroids, etc.)

Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh Class B or C, or acute liver failure

Receiving dialysis or have known renal impairment

Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within days prior to study entry, as determined by the study team

Other medical or psychiatric conditions, in the treating investigator's judgment, that makes the participant inappropriate for the study

Unknown HIV status (subjects must have completed HIV antigen/antibody and viral load testing completed at the screening visit)

Active or latent hepatitis B (subjects must have completed HBV serologies - HbsAg, anti-HBs, and anti-HBc - testing completed at the screening visit)

Current symptoms of severe, progressive, or uncontrolled renal, hematologic, gastrointestinal, pulmonary, cardiac, or neurologic disease, or other medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study

Creatinine clearance (CrCl) \<75mL/min, as calculated by the Cockcroft-Gault equation

Any history of bone fractures not explained by trauma

Confirmed Grade 2 or greater hypophosphatemia

Any Grade 2 or greater toxicity on screening tests and assessments

What this trial measures

EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scaleat Screening, Day 60, Day 90, and Day 180
The EQ-5D-5L is a standardized measure of health status that consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each with 5 levels of severity, and a visual analogue scale (VAS) where individuals rate their overall health from 0 (worst imaginable health) to 100 (best imaginable health).

Trialytics